23 July 2024 : Original article
Engraftment Syndrome in Autologous Hematopoietic Stem Cell Transplant Patients: Incidence, Associated Risk Factors, Features, and Outcomes
Sira Mongkolrat1ABCDEF, Adisak Tantiworawit
2ADE*, Piangrawee Niprapan 2E, Pokpong Piriyakhuntorn 3BDE, Teerachat Punnachet 2E, Nonthakorn Hantrakun 2E, Thanawat Rattanathammethee 2E, Sasinee Hantrakool 2E, Chatree Chai-Adisaksopha 2E, Ekarat Rattarittamrong 2E, Lalita Norasetthada 2E
DOI: 10.12659/AOT.944043
Ann Transplant 2024; 29:e944043
Table 1 Patient characteristics.
| Parameter | Overall (N=124) | Lymphoma (N=67) | Myeloma (N=57) |
|---|---|---|---|
| Female (%) | 55 (44.3) | 27 (40.3) | 28 (49.1) |
| Age, Mean (SD) | 48.0 (±12.3) | 42.6 (±13.2) | 54.3 (±7.2) |
| History | |||
| Hypertension (%) | 24 (19.4) | 8 (11.9) | 16 (28.1) |
| Diabetes mellitus (%) | 6 (4.8) | 2 (3.0) | 4 (7.0) |
| Dyslipidemia (%) | 18 (14.5) | 4 (6.0) | 14 (24.6) |
| Chronic kidney disease (%) | 1 (0.8) | 0 (0) | 1 (1.8) |
| Coronary artery disease (%) | 2 (1.6) | 1 (1.5) | 1 (1.8) |
| Heart failure (%) | 2 (1.6) | 1 (1.5) | 1 (1.8) |
| Thyroid disorder (%) | 3 (2.4) | 1 (1.5) | 2 (3.5) |
| Cirrhosis (%) | 1 (0.8) | 0 (0) | 1 (1.8) |
| Solid malignancy (%) | 2 (1.6) | 1 (1.5) | 1 (1.8) |
| Number of previous regimens | |||
| 1 regimen (%) | 86 (69.4) | 34 (50.8) | 52 (81.2) |
| >1 regimen (%) | 38 (30.6) | 33 (49.2) | 5 (8.8) |
| Previous transplantation (%) | 7 (5.6) | 0 (0) | 7 (12.3) |
| Stem cell source (PBSC) (%) | 124 (100) | 67 (100) | 57 (100) |
| Mobilization | |||
| GCSF alone (%) | 52 (43.7) | 4 (6.0) | 48 (92.3) |
| Chemo-mobilization (%) | 67 (56.3) | 63 (94.0) | 4 (7.7) |
| Plerixafor use (%) | 14 (11.8) | 14 (20.9) | 0 (0) |
| Time to harvest | |||
| Early (within 6 months) (%) | 44 (37.6) | 40 (59.7) | 4 (8.0) |
| Late (beyond 6 months) (%) | 73 (62.4) | 27 (40.3) | 46 (92.0) |
| Stem cell dosage | |||
| TNC ×10 cells/kg, median (IQR) | 10.2 (6.8–16.4) | 9.1 (6.1–13.3) | 12.9 (8.4–21.82) |
| CD34 ×10 cells/kg, median (IQR) | 4.5 (3.3–7.0) | 4.4 (3.3–7.5) | 4.5 (3.2–6.5) |
| Time to transplantation, mean, months (SD) | 9.6 (±5.0) | 8.4 (±3.8) | 11.0 (±5.8) |
| PBSC – peripheral blood stem cell, TNC – total nucleated cell. | |||